M
Melinta
Providing innovative therapies for acute and life-threatening illnesses
About Melinta
Melinta Therapeutics is a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Operating in the healthcare and pharmaceutical markets, Melinta serves hospitals, healthcare providers, and patients who are in need of effective treatments for resistant bacterial infections. The company's business model revolves around research and development (R&D) of new antibiotics, followed by the commercialization of these drugs through sales and partnerships. Revenue is generated primarily through the sale of its antibiotic products and licensing agreements. Melinta's mission is to address the continually evolving threat of bacterial infections by providing innovative solutions that meet the needs of patients and healthcare providers. The company emphasizes collaboration, inclusivity, and agility in its operations to achieve ambitious goals and make a significant impact in the field of infectious diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Parsippany-Troy Hills, United States
- Listing
- IPO 2012
- Employees
- 67
- Open positions
- 11
- Dealroom signal
- 27.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2025 | $300M | — | CorMedix | ↗ |
| POST IPO EQUITYOther financing | May 2018 | $123M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Melinta is 2.8K monthly website visits, up 0% over the last three months. Melinta's team declined 58.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
SR One
EuclidSR Partners- OPOxford Bioscience Partners
Warburg Pincus- VPVatera Healthcare Partners
Series B and later5 investors entered at this stage
MedImmune Ventures- VIVox Equity Partners I
- AVAxiom Ventures
- FFFalcon Flight
Hercules Capital
Other known investors2 additional known investors
Cempra
CorMedix
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Melinta on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Melinta’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.